Becker's Healthcare January 22, 2026
Stool DNA testing climbed sharply after the pandemic began while colonoscopy and fecal immunochemical test use fell, a study of nearly 25 million privately insured Blue Cross Blue Shield beneficiaries found.
The study was published Oct. 21 in JAMA Network Open and was led by researchers from New Haven, Conn.-based Yale University and the University of California Los Angeles. They analyzed 24,973,642 commercially insured beneficiaries ages 50-75 from 2017 to 2024. About half were women, and nearly one-third received at least one colorectal cancer screening test during the study period.
Here are five things to know:
1. Most beneficiaries were ages 50-64, with a smaller share ages 65-75. Regionally, the cohort was concentrated in the South (41.78%), followed by...
Today's Sponsors
Today's Sponsor